Dasher Neuroscience finishes patient enrollment for global Phase 2 trial of AI‑designed YA‑101 targeting multiple system atrophy
Executive summary: Dasher Neuroscience completed patient enrollment for its global Phase 2 clinical trial of the AI‑based drug YA‑101 for multiple system atrophy. The achievement de‑risks the program, moves YA‑101 closer to efficacy read‑out, and showcases the viability of AI‑generated CNS therapeutics.
Who is involved: Dasher Neuroscience Holdings Inc. (TPEx: 7829), clinical trial sites worldwide, and the AI‑driven drug discovery team behind YA‑101.
Likely next: Top‑line data from the Phase 2 study are expected in early 2027, followed by a pre‑IND meeting with the FDA and potential pursuit of orphan‑drug or breakthrough‑therapy designations.
Dasher Neuroscience announced on July 30, 2026 that it has completed patient recruitment for its worldwide Phase 2 study of the AI‑generated drug candidate YA‑101, intended to treat the rare neurodegenerative disorder multiple system atrophy (MSA). The milestone clears a key hurdle for advancing the therapy toward later‑stage testing and potential regulatory filing. Completion of enrollment also validates the company’s AI‑driven discovery platform and may increase investor confidence in its pipeline.
Timeline
- — Dasher Neuroscience schließt die Patientenrekrutierung für die weltweite klinische Phase-2-Studie mit dem führenden KI-basierten Wirkstoffkandidaten YA-101 gegen Multisystematrophie (MSA) ab (PR Newswire)
- — Dasher Neuroscience completa el reclutamiento de pacientes en el ensayo clínico global de fase 2 (PR Newswire)
- — Dasher Neuroscience achève le recrutement des patients dans le cadre de l'essai clinique mondial de phase II portant sur le YA-101, son principal candidat-médicament développé grâce à l'IA, destiné au traitement de l'atrophie multisystématisée (AMS) (PR Newswire)
Analysis — what this means
Likely next events
- Top‑line efficacy and safety results from the Phase 2 YA‑101 trial anticipated Q1 2027.
- Pre‑IND meeting with the U.S. FDA scheduled for mid‑2027 to discuss Phase 2 data.
- Potential application for orphan‑drug designation in the EU and U.S. by late 2027.
- Presentation of Phase 2 findings at the American Academy of Neurology annual meeting in April 2027.
Sectors affected
- Biotechnology
- Central nervous system therapeutics
- AI‑driven drug discovery
Regulatory implications
- Completion of Phase 2 triggers a pre‑IND meeting with the FDA under 21 CFR §312.23 to discuss next steps.
- If results are positive, Dasher may seek FDA Breakthrough Therapy designation for YA‑101 in MSA.
- Orphan‑drug status could be pursued in both the U.S. (Orphan Drug Act) and the EU (Regulation (EC) No 141/2000), providing market exclusivity and fee reductions.
Historical parallels
- Biogen’s Phase 2 completion of aducanumab for Alzheimer’s disease in 2015, which later proceeded to accelerated approval.
- Cerevel’s Phase 2 finish of tavapadon for Parkinson’s disease in 2019, leading to a Phase 3 program.
- Exscientia’s AI‑designed DSP‑1181 entering clinical trials for OCD in 2020, illustrating early AI‑drug milestones.
Key entities
Sources
Open the full interactive case file on Beyond →